Press Releases
Company News
View Summary Medivation Elects Dawn Graham to Board of Directors
Apr 23, 2013
PDF 58.4 KB Add to Briefcase
View Summary Medivation and Astellas Provide Update on PREVAIL
Apr 1, 2013
PDF 60.5 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Mar 6, 2013
PDF 8.9 KB Add to Briefcase
View Summary Medivation Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Corporate Update
Feb 28, 2013
PDF 23.3 KB Add to Briefcase
View Summary Medivation and Astellas Provide Additional Support to Metastatic Prostate Cancer Patients Through Donations to Independent Non-Profit Patient Assistance Organization
Feb 25, 2013
PDF 11.5 KB Add to Briefcase
View Summary Medivation Announces Fourth Quarter and Year-End 2012 Financial Results Teleconference on February 28, 2013
Feb 14, 2013
PDF 9.6 KB Add to Briefcase
View Summary Enzalutamide Data Presented at ASCO GU Symposium
Feb 13, 2013
PDF 70.7 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Feb 6, 2013
PDF 8.9 KB Add to Briefcase
View Summary Medivation Elects Kathryn Falberg to Board of Directors
Feb 4, 2013
PDF 9.7 KB Add to Briefcase
View Summary Enzalutamide Data to Be Presented at ASCO GU Symposium
Jan 30, 2013
PDF 62.9 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Nov 29, 2012
PDF 9.1 KB Add to Briefcase
View Summary Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Nov 9, 2012
PDF 23.5 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Nov 7, 2012
PDF 9.2 KB Add to Briefcase
View Summary Medivation Announces Third Quarter 2012 Financial Results Teleconference on November 9, 2012
Nov 2, 2012
PDF 9.5 KB Add to Briefcase
View Summary Medivation and Astellas Announce New Data From XTANDI(R) (enzalutamide) Pivotal Study
Sep 30, 2012
PDF 64.5 KB Add to Briefcase
View Summary Medivation Effects a 2-For-1 Forward Split of Its Common Stock
Sep 24, 2012
PDF 9.2 KB Add to Briefcase
View Summary Medivation and Astellas Announce XTANDI(R) (Enzalutamide) Is Now Available for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Sep 13, 2012
PDF 63.0 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Sep 4, 2012
PDF 9.2 KB Add to Briefcase
View Summary U.S. FDA Approves XTANDI(R) (enzalutamide) After Priority Review for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Aug 31, 2012
PDF 65.5 KB Add to Briefcase
View Summary Medivation Announces a 2-for-1 Forward Split of Its Common Stock
Aug 28, 2012
PDF 9.4 KB Add to Briefcase
Showing 61-80 of 315 Page: 1 2 3 4 5 6 7 8 ... 16  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Top